Nanotechnology for Age-Related Macular Degeneration

Bo Yang, Ge Li, Jiaxin Liu, Xiangyu Li, Shixin Zhang, Fengying Sun, Wenhua LiuPharmaceutics 2021 · DOI

TL;DR

This review explores how nanotechnology and advanced gene therapy, particularly CRISPR/Cas9, offer promising new avenues for treating Age-Related Macular Degeneration (AMD). By developing novel drug delivery systems and targeting strategies, researchers aim to overcome the limitations of current treatments, such as frequent injections and side effects, ultimately improving patient outcomes.

What Problem Does This Paper Address?

Age-Related Macular Degeneration (AMD) is a leading cause of vision loss in older adults, and current treatments primarily involve repeated intravitreal injections of anti-VEGF drugs. While these treatments can improve visual prognosis, they are expensive, can cause side effects like endophthalmitis, and require frequent administration, leading to poor patient compliance. Furthermore, some patients develop resistance to these therapies. The paper addresses the need for more effective, less invasive, and potentially curative treatments for AMD by reviewing advancements in nanomedicine and gene therapy.

Methods

This paper is a review article, so it doesn't present novel experimental methods. Instead, it synthesizes and discusses existing research on various nanotechnology-based drug delivery systems (NDDS) and gene therapy strategies for AMD. The reviewed NDDS include:

  • Liposomes: Lipid vesicles for encapsulating drugs.
  • Nanomicelles: Self-assembled amphiphilic compounds.
  • Nanoemulsions: Dispersions of oil and water.
  • Nanoparticles: Various types including polymer, metal oxide, and silicon dioxide nanoparticles.
  • Cyclodextrins: Cyclic polysaccharides for encapsulating hydrophobic drugs.
  • Dendrimers: Macromolecular polymers with specific functional groups for targeting.
  • Composite Drug Delivery Systems: Combinations of different delivery platforms.

The paper also discusses gene therapy approaches, focusing on:

  • Gene Replacement/Enhancement Therapy: Using vectors like Adeno-Associated Viruses (AAV) to deliver therapeutic genes or RNA (e.g., siRNA).
  • Gene Editing Therapy: Specifically highlighting the CRISPR/Cas9 system for precise genomic modification.

Novel targeting strategies such as aptamers, RGD peptides, and hyaluronic acid are also reviewed for their potential to enhance drug delivery to specific ocular tissues.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Nanotechnology as a Game-Changer: Nanoparticles and other nanocarriers offer significant advantages over traditional drug delivery for AMD, including improved bioavailability, sustained release, reduced administration frequency, and potentially reduced side effects.
  • CRISPR/Cas9's Precision Potential: Gene editing with CRISPR/Cas9 holds immense promise for directly addressing the genetic underpinnings of AMD, offering a highly targeted and potentially curative approach.
  • Synergistic Strategies are Key: The paper strongly suggests that combining nanotechnology with gene therapy, particularly CRISPR/Cas9 delivered via non-viral vectors, could be the most promising path forward for treating AMD.
  • Targeting is Crucial: Developing strategies to specifically target diseased cells in the retina is vital for maximizing therapeutic efficacy and minimizing off-target effects.
  • Overcoming Ocular Barriers: A major challenge in AMD treatment is delivering drugs effectively to the posterior segment of the eye, and nanocarriers are showing promise in overcoming these biological barriers.

Key Results

As a review, this paper does not present new quantitative results. Instead, it summarizes findings from numerous studies, highlighting the potential of various nanotechnologies and gene therapies. For instance, studies reviewed show that:

  • Liposome-based delivery can reduce the cost and frequency of injections for bevacizumab.
  • Nanomicelles have shown improved epithelial permeability and reduced irritation.
  • CRISPR/Cas9 has demonstrated efficient disruption of VEGF-A expression in retinal cells and reduced choroidal neovascularization in animal models.
  • Targeting strategies like RGD peptides have shown improved delivery of anti-VEGF plasmids to retinal tissues.

Limitations and Future Work

The paper acknowledges several limitations and areas for future research:

  • CRISPR/Cas9 Delivery Challenges: A significant hurdle for CRISPR/Cas9 is the lack of a safe and effective delivery system. While viral vectors like AAV have potential, they also carry risks of cytotoxicity and immunogenicity. Non-viral methods are being explored but have limitations in stability, safety, and efficiency.
  • Off-Target Effects: A major concern with CRISPR/Cas9 is the potential for off-target editing, which researchers are actively working to mitigate through improved enzyme variants and delivery strategies.
  • Nanoparticle Limitations: Some nanoparticle systems face challenges with endosomal escape and nuclear transfer of genetic material, impacting overall delivery efficiency.
  • Cost and Scalability: The development and manufacturing of advanced nanomedicines and gene therapies can be costly, posing a barrier to widespread clinical adoption.
  • Clinical Translation: While promising in preclinical studies, many of these technologies require further rigorous testing and validation in clinical trials to ensure safety and efficacy in human patients.

The authors propose that combining CRISPR/Cas9 with novel non-viral delivery systems represents a promising therapeutic strategy for the future treatment of AMD. Future work should focus on developing safer, more efficient, and cost-effective delivery platforms for gene editing technologies and further exploring targeted nanotherapies.

Summary updated

Abstract

Age-related macular degeneration (AMD) is a degenerative eye disease that is the leading cause of irreversible vision loss in people 50 years and older. Today, the most common treatment for AMD involves repeated intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs. However, the existing expensive therapies not only cannot cure this disease, they also produce a variety of side effects. For example, the number of injections increases the cumulative risk of endophthalmitis and other complications. Today, a single intravitreal injection of gene therapy products can greatly reduce the burden of treatment and improve visual effects. In addition, the latest innovations in nanotherapy provide the best drug delivery alternative for the treatment of AMD. In this review, we discuss the development of nano-drug delivery systems and gene therapy strategies for AMD in recent years. In addition, we discuss some novel targeting strategies and the potential application of these delivery methods in the treatment of AMD. Finally, we also propose that the combination of CRISPR/Cas9 technology with a new non-viral delivery system may be promising as a therapeutic strategy for the treatment of AMD.
BibTeX
@inproceedings{yang2021nanotechnology,
  author = {Bo Yang and Ge Li and Jiaxin Liu and Xiangyu Li and Shixin Zhang and Fengying Sun and Wenhua Liu},
  title = {{Nanotechnology for Age-Related Macular Degeneration}},
  booktitle = {Pharmaceutics},
  year = {2021},
  doi = {10.3390/pharmaceutics13122035},
}
Figure